Marizyme, Inc.

General ticker "MRZM" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $4.4M (TTM average)

Marizyme, Inc. follows the US Stock Market performance with the rate: 11.9%.

Estimated limits based on current volatility of 0.0%: low 0.00$, high 0.00$

Factors to consider:

  • Current price 99.5% below estimated low
  • Earnings for 6 months up through Q2 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [0.06$, 0.24$]
  • 2024-12-30 to 2025-12-30 estimated range: [0.06$, 0.25$]

Financial Metrics affecting the MRZM estimates:

  • Negative: Non-GAAP EPS, $ of -1.45 <= 0.04
  • Negative: Shareholder equity ratio, % of -30.44 <= 22.52
  • Negative: Operating cash flow per share per price, % of -45.57 <= 1.79
  • Negative: negative Net income
  • Negative: negative Operating income
  • Positive: Industry inventory ratio change (median), % of 0 <= 0

Similar symbols

Short-term MRZM quotes

Long-term MRZM plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $0.21MM $0.23MM $0.65MM
Operating Expenses $9.03MM $13.21MM $34.73MM
Operating Income $-8.82MM $-12.97MM $-34.09MM
Non-Operating Income $-2.18MM $-25.19MM $-31.26MM
Interest Expense $0.13MM $2.79MM $30.22MM
R&D Expense $1.68MM $3.98MM $2.18MM
Income(Loss) $-11.00MM $-38.17MM $-65.35MM
Taxes $0.00MM $0.00MM $4.19MM
Profit(Loss)* $-9.74MM $-62.18MM $-69.54MM
Stockholders Equity $47.69MM $17.42MM $-6.70MM
Assets $66.00MM $38.69MM $22.02MM
Operating Cash Flow $-5.79MM $-10.85MM $-4.68MM
Capital expenditure $0.00MM $0.00MM $0.00MM
Financing Cash Flow $6.96MM $7.29MM $4.32MM
Earnings Per Share** $-0.27 $-1.53 $-1.53

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.